Keyphrases
Acute Coronary Syndrome
100%
Endogenous Fibrinolysis
84%
ST-elevation Myocardial Infarction (STEMI)
76%
Atrial Fibrillation
70%
Thrombosis
63%
Percutaneous Coronary Intervention
63%
Fibrinolysis
53%
Bleeding Risk
50%
Dual Antiplatelet Therapy
50%
Antithrombotic Therapy
49%
Meta-analysis
47%
COVID-19
43%
Bleeding
42%
Platelet Reactivity
39%
Ticagrelor
35%
Thrombus
35%
Prothrombotic Status
34%
Global Thrombosis Test
34%
Thrombus Formation
33%
P2Y12 Inhibitors
32%
Aspirin
30%
Clinical Outcomes
27%
Thrombotic
27%
Platelet Function Tests
26%
Acute Myocardial Infarction
26%
Primary Percutaneous Coronary Intervention
26%
Rivaroxaban
26%
Myocardial Infarction
25%
Lysis Time
24%
Occlusion Time
23%
Myocardial Infarction Patients
23%
Antiplatelet Therapy
23%
High Shear
21%
Arterial Thrombosis
21%
Anticoagulation
20%
Systematic Meta-analysis
20%
Thrombolysis
19%
Thrombotic Complications
19%
Spontaneous Reperfusion
19%
Major Adverse Cardiovascular Events
18%
Intensive Care Unit
18%
Cardiovascular Risk
17%
Confidence Interval
17%
Thromboprophylaxis
17%
Randomized Controlled Trial
17%
Clopidogrel
17%
Coagulation
17%
Thrombotic Events
17%
Platelet Thrombus
16%
Cardiovascular Disease
16%
Medicine and Dentistry
Thrombosis
94%
Fibrinolysis
80%
Antithrombotic
73%
Acute Coronary Syndrome
55%
Antiplatelet
48%
Percutaneous Coronary Intervention
48%
Bleeding
47%
Atrial Fibrillation
47%
ST Segment Elevation Myocardial Infarction
44%
Cardiovascular System
43%
Coronary Artery Disease
40%
Myocardial Infarction
40%
Meta-Analysis
37%
Cardiovascular Disease
37%
Anticoagulation
35%
COVID-19
34%
Drug Therapy
33%
Platelet
33%
Thrombus
33%
Thrombocyte Function
32%
Platelet Reactivity
31%
Antithrombotic Therapy
28%
Systematic Review
27%
Acute Heart Infarction
26%
Blood Clotting
26%
Primary Percutaneous Coronary Intervention
26%
Apoplexy
24%
Artery Thrombosis
23%
Function Test
21%
Thrombin
21%
Acetylsalicylic Acid
20%
Blood Clot Lysis
19%
Cardiovascular Risk
17%
Intensive Care Unit
17%
Cardiology
16%
Coronary Artery
16%
Biological Marker
15%
Disease
15%
Blood Stasis
15%
Prevalence
14%
Thromboembolism
13%
Antiplatelet Drug
13%
Out of Hospital Cardiac Arrest
13%
Heart Rhythm
13%
Morphine
13%
Venous Thromboembolism
13%
Fibrinolytic Factor
12%
Thromboprophylaxis
12%
Randomized Controlled Trial
12%
Infarction
12%
Pharmacology, Toxicology and Pharmaceutical Science
Thrombosis
87%
Antiplatelet
82%
Anticoagulant Agent
80%
Acute Coronary Syndrome
80%
ST Segment Elevation Myocardial Infarction
59%
Thrombus
52%
Atrial Fibrillation
47%
Heart Infarction
46%
Cardiovascular Disease
43%
Fibrinolytic Agent
43%
Bleeding
42%
Coronary Artery Disease
38%
Acetylsalicylic Acid
28%
Ticagrelor
28%
Disease
26%
Cerebrovascular Accident
24%
Rivaroxaban
24%
Thrombin
24%
Artery Thrombosis
23%
Cardiovascular Risk
22%
Biological Marker
19%
Prevalence
18%
Acute Heart Infarction
17%
Clopidogrel
16%
Morphine
15%
Combination Therapy
14%
Placebo
14%
Prasugrel
13%
Pharmacotherapy
13%
Randomized Controlled Trial
13%
Out of Hospital Cardiac Arrest
13%
Coronavirinae
13%
Fibrinolytic Factor
13%
Antithrombocytic Agent
12%
Blood Stasis
12%
Dabigatran
12%
Antivitamin K
12%
Vorapaxar
12%
Infarction
11%
Monotherapy
11%
Pharmacodynamics
11%
Purinergic P2Y12 Receptor
10%
Apixaban
10%
Heart Muscle Ischemia
10%
Brain Ischemia
10%
Non ST Segment Elevation Myocardial Infarction
9%
Warfarin
9%
Adverse Outcome
9%
Inflammation
9%
Pharmacokinetics
9%